Latest news with #HAYATherapeutics
Business Wire
6 days ago
- Business
- Business Wire
HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs ® to Accelerate Development of RNA-Guided Therapeutics Platform
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has relocated its U.S. site to Lilly Gateway Labs in San Diego, California, which is operated in partnership with Alexandria Real Estate Equities, Inc. 'Moving our U.S. site to Lilly Gateway Labs marks an important step in the scale-up of our operations,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. Share 'Moving our U.S. site to Lilly Gateway Labs marks an important step in the scale-up of our operations,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. 'The facility offers world-class infrastructure and access to a dynamic scientific environment, providing an ideal setting to continue to advance our RNA-guided therapeutics platform, which is designed to reprogram the root causes of disease with unmatched precision, speed and scalability.' Lilly Gateway Labs, which is part of the Lilly Catalyze360™ model, is a best-in-class innovation hub that connects early-stage biotech companies to the power of Lilly's expertise. The site offers cutting-edge laboratory space, operational support and access to an evolving ecosystem of biotech innovators. HAYA's San Diego office plays a central role in the company's laboratory operations, with a strong focus on advanced multi-modal functional genomics, one of the key components of HAYA's proprietary platform and its Regulatory Genome Atlas. The office will also support business and clinical development, including the advancement of HAYA's first-in-class long non-coding RNA (lncRNA)-targeting therapy HTX-001 for heart failure into the clinic with an initial focus on non-obstructive hypertrophic cardiomyopathy. HAYA recently announced a $65 million Series A financing to accelerate the development of RNA-guided therapeutics that target the regulatory genome to treat chronic and age-related diseases. The round was co-led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly) and Alexandria Venture Investments, the venture arm of Alexandria Real Estate Equities, Inc. At the core of HAYA's platform is the ability to map and decode the regulatory genome. HAYA has built the most comprehensive atlas of the regulatory genome by combining multi-modal functional genomics with proprietary computational and machine learning tools. This allows for the precise identification and modulation of pathogenic cell states across a range of diseases. Last year, HAYA announced a collaboration with Lilly focused on RNA-based drug targets for obesity and related metabolic disorders, making it one of the largest collaborations to date in the regulatory genome field. With its platform, HAYA is advancing a novel approach to develop next-generation precision medicines, and advance its mission of translating deep genomic, epigenomic and transcriptomic insights into novel disease-modifying therapies with potential to improve patients' outcomes by directly reprogramming the cellular drivers of disease. HAYA Therapeutics remains fully independent and retains all assets and intellectual property while at Lilly Gateway Labs. About HAYA Therapeutics HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues. HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego. For more information on the company, please visit our website at Follow us on X and LinkedIn.
Business Wire
08-05-2025
- Business
- Business Wire
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 million in Series A funding. The financing will accelerate the clinical development of HAYA's lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine. This investment emphasizes investor confidence in HAYA's groundbreaking science and positions the company to deliver on its mission of bringing disease-modifying, precision medicines faster and more efficiently to patients. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly), ATHOS, +ND Capital, Alexandria Venture Investments and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinvest and Schroders Capital. "This funding validates our vision for improving the way chronic and complex diseases are treated by creating a new generation of therapies that reprogram disease-driving cell states into healthy ones,' said Samir Ounzain, PhD, HAYA's CEO and co-founder. Share 'This is a defining moment for HAYA as we are advancing our lead program into the clinic. This funding validates our organization, pioneering approach and vision for improving the way chronic and complex diseases are treated by creating a new generation of therapies that reprogram disease-driving cell states into healthy ones,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. 'We're excited that Sofinnova Partners, Earlybird and our syndicate of investors share our vision for the potentially industry changing nature of our platform as we move beyond traditional approaches by leveraging novel therapeutic targets emerging from the regulatory genome.' The company will use the funds to initiate clinical trials for HTX-001, HAYA's first-in-class lncRNA-targeting therapy for heart failure, initially focused on non-obstructive hypertrophic cardiomyopathy (nHCM). In parallel, the company will strengthen its platform capabilities and expand its pipeline of disease-modifying therapies across multiple therapeutic areas—including pulmonary fibrosis, obesity and age-related common and chronic diseases. 'HAYA's platform unlocks the dark genome's therapeutic potential by targeting disease-driving cell states via long non-coding RNAs. This novel approach opens a new frontier in precision medicine, moving beyond traditional target classes to address disease at its epigenetic and cellular roots. Leading this round alongside Earlybird reflects our deep conviction in the HAYA team and their mission to develop safer, more effective therapies across a broad range of indications, including their lead program in nHCM, as they advance it toward the clinic to address a major unmet need,' noted Henrijette Richter, Managing Partner at Sofinnova Partners. The core of HAYA's proprietary platform maps and decodes the biology of the regulatory genome, also referred to as the ' genome's dark matter' or 'Dark Genome," which constitutes 98% of the human genome. While the regulatory genome does not code for proteins it is now recognized as the master control layer of gene expression and cell identity. HAYA has developed the most comprehensive atlas of the regulatory genome by combining integrated multimodal functional genomics with a stack of proprietary computational and machine learning methodologies, enabling the precise identification and modulation of pathogenic cell states across diverse diseases. HAYA's regulatory genome platform enables the development of RNA-guided therapeutics with unprecedented precision, speed and scalability. This next-generation approach is designed to go beyond symptom management and directly reprogram the cellular drivers of disease. To support its strategic growth, HAYA recently assembled an industry-leading C-level suite to drive scalable growth, business and clinical development and expand strategic collaborations with pharmaceutical and technology partners. The company recently announced a partnership with Lilly, one of the largest collaborations to date in the regulatory genome space, focused on RNA-based drug targets for obesity and metabolic disorders. About HAYA Therapeutics HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues. HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities in San Diego. For more information on the company, please visit our website at Follow us on X and LinkedIn. About Sofinnova Partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London, and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is deeply established in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit:
Yahoo
02-05-2025
- Business
- Yahoo
HAYA Therapeutics to Present on RNA-Guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
LAUSANNE, Switzerland & SAN DIEGO, May 02, 2025--(BUSINESS WIRE)--HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, today announced the presentation of data at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans from May 13-17, 2025. The company will showcase its latest advances in an invited presentation focused on HAYA's lead program, HTX-001, an antisense oligonucleotide designed to target the long non-coding RNA (lncRNA) Wisper, the master regulator of fibrosis in the heart, currently in Investigational New Drug-enabling studies and in development for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM). Additionally, HAYA will have a poster presentation on its innovative multimodal omics approach for profiling and designing antisense oligonucleotide-based therapeutics that enables a precise and potent silencing of novel lncRNA targets. "Unlike traditional approaches that block single genes or proteins, we have built a platform to reprogram the fundamental biology that underlies disease," said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. "We are identifying and drugging novel regulatory genome-derived drivers of disease pathogenesis to reprogram sick cells into healthy ones." "Over the past years, we've made significant progress on our lead program, HTX-001, targeting myocardial fibrosis and we anticipate initiating clinical trials in the near future. This forward momentum brings us closer to our ultimate mission: bringing disease-modifying medicines to patients," said Daniel Blessing, Ph.D., Co-founder and CTO of HAYA Therapeutics. Poster Presentation: Title: Harnessing Functional Genomics to Advance the Discovery and Development of Oligonucleotide-Based Therapies Targeting the Regulatory GenomePresenter: Rudi Micheletti, HAYA's Senior Director of Biology and Functional GenomicsPresentation Date/Time: Tuesday, May 13, 2025, 6:00 PM - 7:30 PM CDTLocation: Poster Hall I2Abstract Number: 660 Scientific Symposium: Title: A Wisper from the Heart: Targeting a Cardiac Myofibroblasts-specific LncRNA to Treat Myocardial FibrosisPresenter: Daniel Blessing, HAYA's CTO and Co-founderSession Title: Targeting Myocardium: To The Heart Of The Matter (Organized by the Cardiovascular CGT Committee)Presentation Date/Time: Wednesday, May 14, 2025, 3:45 PM - 5:30 PM CDTLocation: Room 388-390 HAYA's RNA-guided therapeutic platform represents a new approach to treating disease by targeting the root causes at the cellular level. At its core is HAYA's Regulatory Genome Atlas, which maps the connection between noncoding regulatory genome elements, or lncRNAs, and disease-driving cell states by integrating multimodal functional genomics with a stack of proprietary computational tools and machine learning methodologies. This enables the development of genetic medicines that reprogram diseased cells back to healthy ones. About HAYA Therapeutics HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues. HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities in San Diego. For more information on the company, please visit our website at Follow us on X and LinkedIn. View source version on Contacts Media:HAYA TherapeuticsTim IngersollLinnden CommunicationsEmail: tim@ Sign in to access your portfolio
Business Wire
02-05-2025
- Business
- Business Wire
HAYA Therapeutics to Present on RNA-Guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, today announced the presentation of data at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans from May 13-17, 2025. 'Unlike traditional approaches that block single genes or proteins, we have built a platform to reprogram the fundamental biology that underlies disease,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. The company will showcase its latest advances in an invited presentation focused on HAYA's lead program, HTX-001, an antisense oligonucleotide designed to target the long non-coding RNA (lncRNA) Wisper, the master regulator of fibrosis in the heart, currently in Investigational New Drug-enabling studies and in development for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM). Additionally, HAYA will have a poster presentation on its innovative multimodal omics approach for profiling and designing antisense oligonucleotide-based therapeutics that enables a precise and potent silencing of novel lncRNA targets. 'Unlike traditional approaches that block single genes or proteins, we have built a platform to reprogram the fundamental biology that underlies disease,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. 'We are identifying and drugging novel regulatory genome-derived drivers of disease pathogenesis to reprogram sick cells into healthy ones.' 'Over the past years, we've made significant progress on our lead program, HTX-001, targeting myocardial fibrosis and we anticipate initiating clinical trials in the near future. This forward momentum brings us closer to our ultimate mission: bringing disease-modifying medicines to patients,' said Daniel Blessing, Ph.D., Co-founder and CTO of HAYA Therapeutics. Poster Presentation: Title: Harnessing Functional Genomics to Advance the Discovery and Development of Oligonucleotide-Based Therapies Targeting the Regulatory Genome Presenter: Rudi Micheletti, HAYA's Senior Director of Biology and Functional Genomics Presentation Date/Time: Tuesday, May 13, 2025, 6:00 PM - 7:30 PM CDT Location: Poster Hall I2 Abstract Number: 660 Scientific Symposium: Title: A Wisper from the Heart: Targeting a Cardiac Myofibroblasts-specific LncRNA to Treat Myocardial Fibrosis Presenter: Daniel Blessing, HAYA's CTO and Co-founder Session Title: Targeting Myocardium: To The Heart Of The Matter (Organized by the Cardiovascular CGT Committee) Presentation Date/Time: Wednesday, May 14, 2025, 3:45 PM - 5:30 PM CDT Location: Room 388-390 HAYA's RNA-guided therapeutic platform represents a new approach to treating disease by targeting the root causes at the cellular level. At its core is HAYA's Regulatory Genome Atlas, which maps the connection between noncoding regulatory genome elements, or lncRNAs, and disease-driving cell states by integrating multimodal functional genomics with a stack of proprietary computational tools and machine learning methodologies. This enables the development of genetic medicines that reprogram diseased cells back to healthy ones. About HAYA Therapeutics HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues. HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities in San Diego. For more information on the company, please visit our website at Follow us on X and LinkedIn.
